FDA has fast-tracked etirinotecan pegol (NKTR-102) (Nektar Therapeutics) for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine (ATC).

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

FDA fast tracks drug for metastatic breast cancer

Newsletter